Hormonal
Antihyperglycemic therapies reduce the risk of Major Adverse Cardiovascular Events (MACE) in a glycemic-dependent manner, where every 1% reduction in HbA1c is associated with a 14% relative reduction in MACE risk.
If you have type 2 diabetes, achieving a 1% reduction in your HbA1c through medication or lifestyle is associated with a 14% lower risk of major cardiovascular events like heart attack or stroke. This benefit is consistent across various drug classes, suggesting that effective glycemic control is a primary strategy for cardiovascular protection.
every 1% greater reduction in HbA1c was associated with a 14% reduction in the RR of MACE (95% CI 4–24; P = 0.010)
Why this rating
Based on a meta-analysis of 35 randomized controlled trials involving 256,524 patients, providing high statistical power and generalizability.
Source
Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized cardiovascular outcome trials
Masashi Hasebe et al. · Cardiovascular Diabetology · 2023
DOI 10.1186/s12933-023-01773-z
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →